Calidi Biotherapeutics Files 8-K
Ticker: CLDWW · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Calidi Biotherapeutics filed an 8-K on Oct 24, 2025, covering events from Oct 22, 2025. Expect updates on Reg FD, other events, and financials.
AI Summary
Calidi Biotherapeutics, Inc. filed an 8-K on October 24, 2025, reporting on events that occurred on October 22, 2025. The filing includes a Regulation FD Disclosure, Other Events, and Financial Statements and Exhibits. The company, formerly known as First Light Acquisition Group, Inc. until April 6, 2021, is incorporated in Delaware and headquartered in San Diego, California.
Why It Matters
This 8-K filing provides updates on significant company events and financial information, which are crucial for investors to assess the company's current status and future prospects.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on events and financial statements, not indicating any immediate significant risks or positive developments.
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- First Light Acquisition Group, Inc. (company) — Former company name
- October 22, 2025 (date) — Earliest event reported date
- October 24, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- San Diego, California (location) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing for Calidi Biotherapeutics, Inc.?
The 8-K filing serves as a Current Report to disclose significant events, including Regulation FD Disclosures, Other Events, and Financial Statements and Exhibits, as of October 22, 2025.
When was Calidi Biotherapeutics, Inc. formerly known by another name?
Calidi Biotherapeutics, Inc. was formerly known as First Light Acquisition Group, Inc. until April 6, 2021.
What is the principal executive office address for Calidi Biotherapeutics, Inc.?
The principal executive offices are located at 4475 Executive Drive, Suite 200, San Diego, California, 92121.
What is the fiscal year end for Calidi Biotherapeutics, Inc.?
The fiscal year end for Calidi Biotherapeutics, Inc. is December 31.
What is the SIC code for Calidi Biotherapeutics, Inc.?
The Standard Industrial Classification (SIC) code for Calidi Biotherapeutics, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 604 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2025-10-24 17:16:07
Key Financial Figures
- $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 13KB
- ex99-2.htm (EX-99.2) — 26KB
- ex99-1_001.jpg (GRAPHIC) — 254KB
- ex99-1_002.jpg (GRAPHIC) — 500KB
- ex99-1_003.jpg (GRAPHIC) — 409KB
- ex99-1_004.jpg (GRAPHIC) — 209KB
- ex99-1_005.jpg (GRAPHIC) — 401KB
- ex99-1_006.jpg (GRAPHIC) — 545KB
- ex99-1_007.jpg (GRAPHIC) — 262KB
- ex99-1_008.jpg (GRAPHIC) — 285KB
- ex99-1_009.jpg (GRAPHIC) — 353KB
- ex99-1_010.jpg (GRAPHIC) — 438KB
- ex99-1_011.jpg (GRAPHIC) — 340KB
- ex99-1_012.jpg (GRAPHIC) — 303KB
- ex99-1_013.jpg (GRAPHIC) — 270KB
- ex99-1_014.jpg (GRAPHIC) — 320KB
- ex99-1_015.jpg (GRAPHIC) — 408KB
- ex99-1_016.jpg (GRAPHIC) — 323KB
- ex99-1_017.jpg (GRAPHIC) — 268KB
- ex99-1_018.jpg (GRAPHIC) — 342KB
- ex99-1_019.jpg (GRAPHIC) — 347KB
- ex99-1_020.jpg (GRAPHIC) — 227KB
- ex99-1_021.jpg (GRAPHIC) — 344KB
- ex99-1_022.jpg (GRAPHIC) — 240KB
- 0001493152-25-019353.txt ( ) — 10431KB
- cldi-20251022.xsd (EX-101.SCH) — 3KB
- cldi-20251022_lab.xml (EX-101.LAB) — 33KB
- cldi-20251022_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: October 24, 2025 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer